# Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

> **NCT05044819** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Jazz Pharmaceuticals** · enrollment: 154 (actual)

## Conditions studied

- Lennox Gastaut Syndrome
- Dravet Syndrome
- Tuberous Sclerosis Complex

## Interventions

- **DRUG:** Cannabidiol

## Key facts

- **NCT ID:** NCT05044819
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-07
- **Primary completion:** 2027-08-01
- **Final completion:** 2028-03-31
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05044819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05044819, "Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05044819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*